Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity
المؤلفون المشاركون
Ebara, Mitsuhiro
Nabil Ahmed, Ahmed
Elshemy, Mohamed M.
Asem, Medhat
Abdel-Motaal, Marwa
Gomaa, Heba F.
Zahran, Faten
Uto, Koichiro
المصدر
Oxidative Medicine and Cellular Longevity
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-11، 11ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-05-29
دولة النشر
مصر
عدد الصفحات
11
التخصصات الرئيسية
الملخص EN
Cancer, as a group, represents the most important cause of death worldwide.
Unfortunately, the available therapeutic approaches of cancer including surgery, chemotherapy, radiotherapy, and immunotherapy are unsatisfactory and represent a great challenge as many patients have cancer recurrence and severe side effects.
Methotrexate (MTX) is a well-established (antineoplastic or cytotoxic) chemotherapy and immunosuppressant drug used to treat different types of cancer, but its usage requires high doses causing severe side effects.
Therefore, we need a novel drug with high antitumor efficacy in addition to safety.
The aim of this study was the evaluation of the antitumor efficacy of zinc oxide nanoparticle (ZnO-NPs) and sorafenib alone or in combination on solid Ehrlich carcinoma (SEC) in mice.
Sixty adult female Swiss-albino mice were divided equally into 6 groups as follows: control, SEC, MTX, ZnO-NPs, sorafenib, and ZnO-NPs+sorafenib; all treatments continued for 4 weeks.
ZnO-NPs were characterized by TEM, zeta potential, and SEM mapping.
Data showed that ZnO-NPs synergized with sorafenib as a combination therapy to execute more effective and safer anticancer activity compared to monotherapy as showed by a significant reduction (P<0.001) in tumor weight, tumor cell viability, and cancer tissue glutathione amount as well as by significant increase (P<0.001) in tumor growth inhibition rate, DNA fragmentation, reactive oxygen species generation, the release of cytochrome c, and expression of the apoptotic gene caspase-3 in the tumor tissues with minimal changes in the liver, renal, and hematological parameters.
Therefore, we suggest that ZnO-NPs might be a safe candidate in combination with sorafenib as a more potent anticancer.
The safety of this combined treatment may allow its use in clinical trials.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Nabil Ahmed, Ahmed& Elshemy, Mohamed M.& Asem, Medhat& Abdel-Motaal, Marwa& Gomaa, Heba F.& Zahran, Faten…[et al.]. 2020. Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity. Oxidative Medicine and Cellular Longevity،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1203691
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Nabil Ahmed, Ahmed…[et al.]. Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity. Oxidative Medicine and Cellular Longevity No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1203691
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Nabil Ahmed, Ahmed& Elshemy, Mohamed M.& Asem, Medhat& Abdel-Motaal, Marwa& Gomaa, Heba F.& Zahran, Faten…[et al.]. Zinc Oxide Nanoparticle Synergizes Sorafenib Anticancer Efficacy with Minimizing Its Cytotoxicity. Oxidative Medicine and Cellular Longevity. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1203691
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1203691
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر